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Purpose

Medical trainees are likely at differential risk of exposure to COVID-19 per respective clinical activity.
We sought to determine the seroprevalence of COVID-19 antibody (Ab) among resident and fellow
physicians with varying degrees of exposure to COVID-19.

Methods

 cross-sectional study of Milwaukee-based resident and fellow physicians, encompassing December
A
2019–June 2020, was conducted. Relevant variables of interest were ascertained by survey and payroll
data, and Abbott ARCHITECT Ab test (index cut-off of ≥1.4) was performed. Descriptive statistics were
generated, with 95% CI calculated for the study’s primary outcome of seroprevalence.

Results

 mong survey respondents (92 of 148, 62%), 61% were male, 44% were non-White, mean age was
A
31 years, 94% had no underlying conditions, and 52% were either family or internal medicine residents.
During the study period, ≥32% reported cough, headache, or sore throat and 62% traveled outside of
Wisconsin. Overall, 83% thought they had a COVID-19 exposure at work and 33% outside of work; 100%
expressed any exposure. Of those exposed at work, 56% received COVID-19 pay, variously receiving
69 mean hours (range: 0–452). Ultimately, 82% (75 of 92) had an Ab test completed; 1 individual (1.3%;
95% CI: 0.0–3.9) tested seropositive, was not previously diagnosed, and had received COVID-19 pay.

Conclusions

 he low Ab seroprevalence found in resident and fellow physicians was similar to the concurrently
T
reported 3.7% Ab-positive rate among 2456 Milwaukee-based staff in the same integrated health
system. Ultimately, COVID-19 seroconversion may be nominal in properly protected resident and
fellow physicians despite known potential exposures. (J Patient Cent Res Rev. 2022;9:75-82.)
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A

s of December 2021, the COVID-19 infection
caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in
approximately 50 million cases and 800,000 deaths
in the United States.1 Early on, the etiologic virus was
challenging to predict, control, and track.2-4 For obvious
reasons, health care workers, including physicians,
are at higher risk for acquisition of COVID-19.5 These
individuals also can be exposed outside of the work
environment, especially given the significant percentage
of spread from presymptomatic and asymptomatic
individuals.6,7

In most integrated health systems, resident and fellow
physicians provide frontline care to inpatients and
outpatients in many departments, and their safety is
the responsibility of the institution.8 Similar to other
health care workers, residents and fellows are likely at
differential risk of exposure to COVID-19 based on the
specific clinical activities in which they engage.7 The
impact of the COVID-19 pandemic on operations and
continuing accreditation of residencies and fellowships is
already observed to be substantial.cf.8-14 Current and future
protection of these trainees, as well as their co-workers
and family, is vitally important.

Corresponding author: Dennis J. Baumgardner,
960 N. 12th St., Milwaukee, WI, 53233
(dennisj.baumgardner@outlook.com)

The role of serology is essential for understanding
COVID-19 past exposure and future planning.15,16
Currently, it is still being determined what level of antibody
response confers immunity and how long it may last.17-19 In
Wisconsin, at the time of study initiation, limited testing
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for acute COVID-19 infection had been positive in 9% of
all individuals tested and 12% of all health care workers
tested; 10.5% of statewide COVID-19 immunoglobulin
G (IgG) antibody (Ab) tests performed for various
reasons were positive (internal data on file May 11,
2020). The percentage of our own institution’s residents
and fellows who had contracted COVID-19 infection
(including asymptomatic, presymptomatic, and minimally
symptomatic disease) was also unknown at the time.
Therefore, this study’s primary aim was to determine
the overall seroprevalence of COVID-19 IgG Ab in
relatively young, healthy adults who are resident and
fellow physicians. We also wished to determine the
seroprevalence of Ab in these individuals by specialty
type, associations of positive Ab tests by degree and types
of clinical activities, and number of known exposures
to COVID-19 patients or persons outside of the work
setting. We hypothesized that the overall seroprevalence
of COVID-19 IgG Ab among residents and fellows would
be higher than that of the general population of similar age
in the surrounding community and that the seroprevalence
would differ by type of clinical activity subjects were
involved. As this study was set in a city (Milwaukee,
Wisconsin) during a time of medium risk (June 2020), we
believe the results to be generalizable to other U.S.-based
training sites and hence may inform graduate medical
education program directors, institutional officials, and
oversight bodies such as the Accreditation Council for
Graduate Medical Education (ACGME) of the (perhaps
differential) risk of trainee infection with COVID-19.

METHODS

Study Population, Design, Data Sources

This targeted, cross-sectional study aimed to estimate
the seroprevalence of COVID-19 viral infection20 among
all residents and fellows employed by a single integrated
health system and based in Milwaukee, Wisconsin (n=148).
Similar to other institutions, many of the medical trainees
in generalist or specialty programs were redeployed to
cover or perform extra inpatient duties, including care of
COVID-19 patients.8,10 These individuals were afforded
appropriate personal protective equipment (PPE), including
gowns, face shields, and N95 respirators.
Subjects were asked to voluntarily participate in the
study, irrespective of training program, primary clinical
setting, and relevant demographics. This study received
local institutional review board approval, and subjects
acknowledged informed consent information embedded
within the initial pages of the survey.
Participants were invited by the manager of research for
our system's graduate medical education department via
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email on June 5, 2020, to complete the online survey
using REDCap, a mature, secure web application for
building and managing online surveys and databases.21,22
Those among the 148 residents and fellows who did not
acknowledge consent for participation, who indicated
they were not based in Milwaukee, or who did not
participate in a program within the last 8 training
program block intervals were excluded. The survey
queried respondents regarding the 8 4-week duration
curriculum rotation block intervals within the time
period of December 2019 to June 2020 and collected
demographic characteristics, working conditions,
household size, previous clinical symptoms, preexisting
medical conditions, working conditions by time period,
household size, known COVID-19 exposures, acute
COVID-19 testing history and results, subject Ab test
result prediction, desires for a positive versus negative
test result, and reasons for desiring a particular result.
Additionally, the timing by rotation block and number
of hours of special COVID-19 pay received during the
survey time period was linked to each completed survey
by the research manager for the last 4 blocks.
Antibody Assay

Following survey completion, participants were sent a
requisition to complete an Ab test if they had not already
completed one. Willing subjects had a SARS-CoV-2
(nucleocapsid protein) IgG Ab test (ARCHITECT®, Abbott)
performed on their serum in our health system laboratory
per manufacturer protocol. Tests were drawn during June–
July 2020. Results and the index value (numerical test
result) were recorded for each test; a value of ≥1.4 was
considered seropositive per manufacturer specifications.
All test results regardless of positivity were reported to the
appropriate health department and to the subjects.
Statistical Analysis

The primary outcome of interest for this study was to
estimate seroprevalence of COVID-19 antibodies among
all eligible and willing resident and fellow physicians. The
minimum sample size was determined by the previous
surveillance of COVID-19 within our health system at
study onset. Using the then-estimated seroprevalence of
10.5% (internal data on file May 8, 2020), we needed to
enroll an estimated minimum of 78 participants in order
to estimate the true population proportion of COVID-19
seroprevalence, with a required margin of error of 5% and a
confidence level of 95%. A finite population correction was
applied to the sample size formula. Descriptive statistics
were performed to describe the demographic characteristics
and outcome of study participants. Frequencies were
calculated with 95% CI, as appropriate by variable type
and the distribution of values, and potential associations
analyzed by simple linear regression.
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RESULTS

Survey Results

The overall survey response rate was 62% (92 of 148,
Figure 1). Survey responses varied by program type
and training year (Table 1). Demographic details of the
surveyed residents and fellows are presented in Online
Supplemental Table S1. Most subjects had no underlying
chronic illnesses, and the minority reported symptoms
typical of acute symptomatic COVID-19 infection,23 none
of which were apparently severe (Online Supplemental
Table S2).

household (22%) or other exposures (33%). Travel
outside of Wisconsin was common during the time
period; 61% of participants traveled during blocks before
the state-issued lockdown (November 18, 2019–March 8,
2020) and 26% during blocks after the lockdown.

Table 3 describes the number of encounters with
COVID-19–positive patients by training program.
Special duty COVID-19 pay was used as a proxy for
patient exposure, and it was variously received by 40
trainees in this study between March 9, 2020, and June 30,
FIGURES
2020. Online Supplemental Table S3 depicts aggregate
receipt of hours of this special pay by trainee specialty;
Table 2 details the exposure histories of those surveyed.
Figure 1. Breakdown of resident and fellow physicians approached to participate.
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the
most
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COVID-19
polymerase chain reaction test results for COVID-19.
pay by the number of reported COVID-19–positive
All reported some type of exposure, with the majority
patient encounters for the 40 subjects who received it.
(83%) reporting patient exposures, and fewer reporting
The association was statistically significant but explains
a minority of the variation.
Of 92 survey respondents, 16 (17%) believed they
had COVID-19 sometime during the study period. In
addition, 18 of 92 (19%) were previously tested for
acute COVID-19, of which 1 tested positive (this person

148 Resident and
fellow physicians
approached

92 (62.2%)
Eligible/Completed
survey

Table 1. Response Rate to Survey Invitation by
Postgraduate Year and Training Program (N=148)
Respondent status
Postgraduate year (PGY)
   1
2
3
   4
5
   6
7
Training programa
   Family medicine
   Internal medicine
   Radiology
   Transitional year
   Cardiology fellowshipb
   Obstetrics and gynecology
   Hospice/palliative care fellowship
   Gastrointestinal fellowship
   Surgical oncology fellowship
Total

17 (18.5%) had
been tested for
acute COVID‐19

1 (1.1%) had tested
positive for acute
COVID‐19

75 (81.5%)
Completed SARS‐
CoV‐2 IgG antibody
testing

1 (1.3%) was
seropositive (95% CI:
0.0–3.9; IgG value:
3.62 ng/ml)

Individual was
not previously
diagnosed and
received COVID‐
19 pay

COVID-19

Figure 1. Breakdown
of resident and fellow
physicians approached
to participate.

n (%)
33 (36%)
17 (18%)
24 (26%)
8 (9%)
5 (5%)
2 (2%)
3 (3%)
25 (80.6%)
23 (60.5%)
13 (65.0%)
10 (71.4%)
11 (40.7%)
7 (62.2%)
2 (100%)
1 (33.3%)
0 (0%)
92 (62.2%)

Percentages, other than for “Total,” were calculated within
each program group.
a

“Cardiology fellowship” includes all cardiology subspecialty
fellowship programs.
b
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Table 2.  Previous COVID-19 Testing and Exposure Among All Respondents Throughout Any Time Period in
Study (N=92)
Known testing and exposure to COVID-19

n (%)

Previous testing
   Tested for acute COVID-19
   Tested positive for acute COVID-19

17 (18.5%)
1 (1.1%)

Household exposure
   Had a household member with known exposure
   Exposed by a confirmed positive household membera

20 (21.7%)
4 (4.5%)

Patient exposure by training programb
   Family medicine
   Internal medicine
   Radiology
   Transitional year
   Cardiology fellowshipc
   Obstetrics and gynecology
   Hospice/palliative care fellowship
   Gastrointestinal fellowship
Total

23 (92.0%)
20 (87.0%)
6 (46.2%)
10 (100%)
9 (81.8%)
6 (85.7%)
1 (50.0%)
1 (100%)
76 (82.7%)

Other exposure
   Outside work and home
Any exposure

30 (32.6%)

d

   Household member or patient or other

92 (100%)

Travel
   International
   Domestic

14 (15.2%)
55 (59.8%)

A confirmed positive household member was determined by clinical signs and symptoms only. There were no cases of
household exposure to a COVID-19–positive person where the positive status was confirmed by a COVID-19 test.
a

b
c

Percentages, other than for “Total,” were calculated within each program group.

“Cardiology fellowship” includes all cardiology subspecialty fellowship programs.

d

For “Any exposure,” household exposure was defined as any household member with a known exposure.

did not take the Ab test). When asked if they wished to
be seropositive, 59 of 92 (64%) responded affirmatively.
Primary reasons for wanting to test seropositive (openended question) included having immunity to COVID-19
(n=42, 71%), peace of mind (n=17, 29%), and concern about
an asymptomatic infection or possible transmission (n=14,
24%). Other reasons included lower risk of transmission
(n=8, 14%), protect family (n=7, 12%), ability to donate
plasma (n=4, 7%), comfort treating patients (n=4, 7%),
confirmation of previous COVID-19 symptoms (n=3, 5%),
and exemption from vaccination (n=1, 2%).

0.0–3.9). This trainee had not been previously diagnosed
with COVID-19, was not previously tested for acute
COVID-19, reported no COVID-19–related symptoms
for the duration of the study period, and had no underlying
health conditions (as defined in Table 3). Approximately
64 hours of COVID-19 pay was given to this participant
during March 9, 2020, to April 5, 2020. There was no
known domestic or international travel for this participant,
who lived in a household with 3 other persons who had
not tested positive for COVID-19 during the study period.
There was no known exposure outside of work and home.

Seroprevalence

All remaining 74 Ab-tested subjects had index values
well below the cut-off of 1.4 (Figure 3). The association
analysis planned in the study design was not performed
due to there being a single positive test result.

Ab testing was performed on 75 individuals (51% of
all potential subjects, 82% of those surveyed) (Figure
1). One individual tested seropositive (1.3%; 95% CI:
78

JPCRR • Volume 9, Issue 1 • Winter 2022

COVID-19

Table 3.  Patient Encounters With COVID-19–Positive Patients by Training Program
Mean encounters per
respondent (SD)
10.1 (8.9)
29.7 (30.2)
3.7 (7.7)
15.8 (10.8)
7.5 (8.8)
11.1 (6.4)
9.5 (13.4)
-

Training program
Family medicine
Internal medicine
Radiology
Transitional year
Cardiology fellowshipa
Obstetrics and gynecology
Hospice/palliative care fellowship
Gastrointestinal fellowship
Total encounters
a

Total encounters
within program (%)
252 (19.5%)
653 (50.6%)
48 (3.7%)
158 (12.2%)
82 (6.4%)
78 (6.0%)
19 (1.5%)
1 (0.10%)
1291 (100%)

“Cardiology fellowship” includes all cardiology subspecialty fellowship programs.

Figure 2. Total COVID-19 pay by number of COVID-19–positive patient encounters (n=40). Note: n=40

SD,includes
standard
deviation.
only those
who were exposed to a COVID-19 patient and received COVID-19 pay. *Logarithmic
transformation performed on values of total COVID-19 pay and total patient encounters as data was
highly skewed.
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At the time of this writing, we found no published
reports of COVID-19 seroprevalence solely among
resident and fellow physicians based in the United
States. COVID-19 IgG seroprevalence was quite low
in our population of residents and fellows (1.3%; 95%
CI: 0.0–3.9) despite various and universal self-report of
exposures. There are many possible explanations for this
prevalence rate, which was similar to the reported 3.7%
Ab-positive rate among 2456 Milwaukee-based staff in
our same integrated health system.24 Ab rates among
COVID-19

100

120

Figure 2. Total COVID-19
pay by number of
COVID-19–positive patient
encounters (n=40). Note:
n=40 includes only those
who were exposed to a
COVID-19 patient and
received COVID-19 pay.
*Logarithmic transformation
performed on values of total
COVID-19 pay and total
patient encounters as data
was highly skewed.

those with clinical roles (residents and fellows not
delineated) from the combined Wisconsin and Illinois
portions of our health system was 3.5%, compared to
3.0% in nonclinical staff,24 both of which are similar
to our study’s findings. Our study population’s Ab
prevalence rate was lower than the 6.5% reported for
systemwide staff deemed “COVID-19 clinical”24 and
(nonsignificantly) lower than the 7.0% (95% CI: 2–20)
prevalence found in 43 echocardiography and stress
laboratory staff at the primary medical center that also
hosts our study’s medical trainees.25
aah.org/jpcrr
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Figure 3. Negative IgG values by training program for all participants who received an antibody test.
*Cardiology includes all cardiology subspecialty fellowship programs. Gastrointestinal fellowship was
excluded as there was only 1 participant.
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0.35
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0.00

Figure 3. Negative IgG values by training program
for all participants who received an antibody test.
*Cardiology includes all cardiology subspecialty
fellowship programs. Gastrointestinal fellowship was
excluded as there was only 1 participant.

Our results are similar to the <1% seroconversion
(utilizing the IgG ELISA [EUROIMMUN] and Elecsys®
[Roche Diagnostics] assays) among well-protected health
care workers not known to have had acute COVID-19
infection following an outbreak in a German perinatal
center26 and to the 2.9% seroconversion among internal/
family medicine physicians and 0% conversion among
pulmonary/critical care physicians in Chicago.27 The
latter study was performed during a similar time period
as ours and used the same Ab test (index value cut-off
not reported), but it did not differentiate residents and
fellows. That study had an overall Ab positivity rate
among all patient-facing and non-patient-facing health
care workers of 4.3%, among whom 17.5% believed
they had experienced nonhospital COVID-19 exposure.27
Therefore, COVID-19 seroconversion may be low in
properly protected residents and fellows and proportional
to other protected health care workers.
Our seroprevalence rate was below that of physicians
(6.1%, not specific for trainees) in 27 hospitals in the
Detroit, Michigan, area tested during a similar time
period utilizing VITROS (Ortho Clinical Diagnostics).28
Of various units, seroprevalence was highest among
physicians in hospital emergency departments (8.2%).
Consistent use of N95 and surgical facemasks decreased
the likelihood of seropositivity among hospital workers in
this study, with household COVID-19–positive exposures
increasing likelihood of seropositivity.28
80
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Talbot and colleagues performed a cross-sectional study
of 474 health care workers at a single New York hospital
utilizing a survey and nucleocapsid-detecting COVID-19
IgM/IgG Ab assay (DPP®, Chembio Diagnostics, Inc.).29
Various physicians were included, but residents and fellows
were not delineated. Seroprevalence was lower (12.7%) in
physicians with “frontline” potential COVID-19 patient
exposure than in “other” physicians (16.5%). Overall, Ab
prevalence was lower (14.2%) among health care workers
with high time exposure to COVID-19 patients than in
those with minimal time exposure (18.9%). The authors
concluded that their overall seropositivity (16.9%) was
similar to the general population of New York during
that time (14%) and that COVID-19 infection among
health care workers may result from community rather
than occupational exposure.29 A recent systematic review
indicated that COVID-19 seroprevalence is generally
higher among those 1) working in a COVID-19 unit, 2)
having shortage of PPE, and 3) having known or suspected
household COVID-19 contact.7 It is unclear if our study’s
comparatively lower prevalence rate was due to relatively
lower COVID-19 patient census, fewer COVID-19 patient
contact hours, better or more familiar PPE usage, different
physician habits, or other factors. A minority of our subjects
reported household contact exposure. While estimates vary
widely,30 a study of Wisconsin and Tennessee households
during the approximate time of our study showed an overall
secondary household infection rate of 53%.31
Another possible explanation for our study’s low
prevalence is that some number of our subjects had
become acutely infected with COVID-19 but did not
have significant Ab levels at the time of testing (perhaps
as much as 4 months following exposure). While there
are reports of waning IgG Ab beyond 3 months from
acute illness onset, especially in milder disease,17,18 a
study of 1215 COVID-19 patients in Iceland suggests that
Ab levels do not decline within 4 months of diagnosis.19
Studies from Portugal and New York report Ab detection
for up to 5–6 months.32,33 Thus, it is likely that Ab would
persist in previously infected subjects until the time of
assay in our study. Conversely, subjects who had become
infected with COVID-19 within 2–3 weeks prior to the
Ab test, particularly with mild disease, may have yielded
a negative result for this IgG test.34 Based on our health
system’s COVID-19 pay data, this would be expected to
be a small number of potential subjects.
Regarding attitudes held by residents and fellows on prior
infection, more than half of the respondents noted they
hoped their Ab test would come back positive. Most of those
reportedly hoping for a positive test explained that stance
as wanting evidence of personal immunity, even though
national COVID-19 guidance advised that Ab testing not
be considered a reliable measure of immunity status.
COVID-19

Regarding the specific ARCHITECT Ab assay employed
in this study, it compares favorably to other commercial
assays in prior studies,35-39 with up to 98.9% agreement
for consensus negative and 99.7% for consensus positive
tests, as compared to other assays.36,39
Limitations

In addition to the aforementioned discussion points,
limitations of our study include a relatively modest
sample of resident and fellow physicians in a single
metropolitan area, reliance on subject recall, and inability
to perform subset analysis due to having only a single
positive subject. Additionally, not all ACGME program
disciplines were represented in our institution. These
issues limit generalizability. Acute COVID-19 testing
was not performed on most subjects in order to correlate
with our very low Ab prevalence. Therefore, our results
must be put in context of the local community prevalence
(approximately 1% cumulative acute cases) at the time
of the study.40 An updated study by the Survey of the
Health of Wisconsin revealed that Ab prevalence among
Wisconsin participants increased 4–5-fold between
summer (1.6%) and fall (6.8%) of 2020, with reported
prevalence of 9.2% in southeastern Wisconsin in the
latter time period.41

CONCLUSIONS

COVID-19 IgG seroprevalence was quite low in this
population of U.S. Midwest, urban-based resident and
fellow physicians despite all subjects reporting various
potential exposures to infectious patients. As these
findings were similar to those of other reported regional
Ab rates among well-protected hospital staff, it appears
that secondary acquisition of COVID-19 may remain
low (and similar to community levels, as previously
suggested29) in properly protected residents and fellows
regardless of clinical activities.
Patient-Friendly Recap
• Physicians-in-training, such as residents and
specialty fellows, are variously exposed to patients
with COVID-19 and must be protected from
catching the disease.
• The authors surveyed resident and fellow
physicians about their risk factors and potential
exposures to COVID-19 during early months of the
pandemic in Milwaukee, Wisconsin.
• Only 1 of 75 tested residents and fellows had
evidence of prior COVID-19 disease based on a
serum antibody (nucleocapsid protein) test.
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